ResearcherAsan Medical CenterActive in the last 2 years
Hyunseok Yoon
Matched on ORCID iD 0009-0000-4502-8021; OpenAlex author ID A5090264078. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 3
- Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOX. Co-author DOI 10.3389/fonc.2026.1762299↗
- Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
- Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… First author DOI 10.4143/crt.2023.452↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Changhoon Yoo · 3 shared papers, 2023–2026 · strength 0.61
- Paper Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated w… DOI 10.3389/fonc.2026.1762299↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Hyehyun Jeong · 2 shared papers, 2024–2026 · strength 0.45
- Paper Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated w… DOI 10.3389/fonc.2026.1762299↗
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Ki Byung Song · 2 shared papers, 2023–2024 · strength 0.32
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Kyu‐pyo Kim · 2 shared papers, 2023–2024 · strength 0.32
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Do Hyun Park · 2 shared papers, 2023–2024 · strength 0.32
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Dae Wook Hwang · 2 shared papers, 2023–2024 · strength 0.32
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Tae Jun Song · 2 shared papers, 2023–2024 · strength 0.32
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Seung‐Mo Hong · 2 shared papers, 2023–2024 · strength 0.32
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Baek‐Yeol Ryoo · 2 shared papers, 2023–2024 · strength 0.32
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Song Cheol Kim · 2 shared papers, 2023–2024 · strength 0.32
- Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Sun Young Kim · 1 shared paper, 2026 · strength 0.29
- Jong Hyuk Lee · 1 shared paper, 2026 · strength 0.29
- Yejong Park · 1 shared paper, 2024 · strength 0.16
- Jin‐hong Park · 1 shared paper, 2024 · strength 0.16
- Bong Jun Kwak · 1 shared paper, 2024 · strength 0.16
- Inkeun Park · 1 shared paper, 2024 · strength 0.16
- Dong Wan Seo · 1 shared paper, 2024 · strength 0.16
- Sang Soo Lee · 1 shared paper, 2024 · strength 0.16
- Dongwook Oh · 1 shared paper, 2024 · strength 0.16
- Dong-Hoon Lim · 1 shared paper, 2023 · strength 0.16
- Jaewon Hyung · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.